Addresses
The effective use of cardiac-specific troponin estimations in the diagnosis of acute myocardial infarction (AMI) is clouded by the imprecise definition surrounding the decision limits. This has led to a wide variation of criteria for the diagnosis of myocardial infarction. A survey of troponin measurements in Welsh laboratories, undertaken in 2003 under the auspices of the All Wales Clinical Biochemistry Audit Group, revealed significant variations in laboratory and clinical practice. Extensive discussion and consultation led by a working group of clinical biochemists and cardiologists in Wales culminated in recommendations concerning the use of troponin assays to establish myocardial damage.
The key recommendations are: Cardiac troponin (T or I) should be the first-line test for myocardial damage; Two samples should be collected, at admission and 12-24 h later. The first sample is used for 'rule in' purposes, but not to 'rule out' myocardial damage;
Only one threshold (cut-off) value for troponin should be quoted on laboratory reports, values above which are indicative of myocardial damage.
A study by the Wales External Quality Assurance Scheme (WEQAS) enabled the derivation of the recommended cut-off concentrations of troponin for defining myocardial damage, defined for each assay as the concentration that can be reliably distinguished, with a confidence interval of 99%, from the 99th percentile reference limit.
These recommended standards provide a rationale for a uniform approach for troponin assays for patients with chest pain, working towards a standardized approach to the diagnosis and management of patients presenting with acute coronary syndromes. 
Overview of current guidance
The 1979 WHO criteria for the diagnosis of acute myocardial infarction (AMI) 1 required two out of three of:
Classical symptoms (particularly chest pain); Electrocardiographic (ECG) changes; Serial changes in enzyme markers, speci¢cally creatine kinase (CK; total or MB isoenzyme).
The diagnosis of clinical AMI required su⁄cient myocardial necrosis to elevate CK and/or produce characteristic ECG changes. Other diagnostic labels such as non-ST elevation AMI (NSTEMI) and unstable angina implied lesser changes in ECG and/or CK, all these diagnoses being associated with an adverse coronary prognosis. The same criteria were used initially to establish clinical decision points for cardiac troponin as for CK. 2, 3 Troponin cut-o¡ points for myocardial infarction (MI) were high, resulting in the classi¢cation of patients who had su¡ered myocardial damage but who did not ful¢l the WHO de¢nition of AMI as having troponin-positive unstable angina or minimal myocardial damage. A 2004 discussion paper by a British Cardiac Society working group 4 proposed that this old de¢nition of AMI be re-invented.
It has now been shown that any detectable troponin elevation is associated with an increased risk of major adverse cardiac events (MACE) and that this risk increases with the magnitude of the troponin elevation. 5, 6 A clinical continuum called Acute Coronary Syndrome (ACS) has now been recognized, together with the importance of detecting even a small amount of myocardial injury. It has also been recognized that an increased troponin concentration indicates the presence of myocardial damage, but does not in itself diagnose the cause of the damage.
In 2000, the European Society of Cardiology (ESC) and American College of Cardiology (ACC) issued a consensus document 7 rede¢ning AMI, placing greater emphasis on cardiac troponin to detect myocardial damage, thus e¡ectively lowering the diagnostic threshold. This document stated that, for the diagnosis of AMI, there must be a rise and fall in the serum cardiac troponin concentration and at least one of the following:
Ischaemic symptoms; New ECG changes (ST--T segment changes and/or Q-waves);
A speci¢c setting of coronary artery intervention (e.g. coronary angioplasty).
'Non-infarct'clinical settings associated with an elevated cardiac troponin concentration include heart failure, pulmonary embolism, tachyarrhythmias, trauma, surgery, myocarditis and renal impairment.
Cut-off levels
The ESC/ACC Consensus paper 7 proposed that a cardiac troponin concentration exceeding the 99th percentile for a healthy population is positive for myocardial damage. However, this value is so low that current assays are not su⁄ciently reproducible or accurate at this low level. Therefore, it was recommended that the value closest to the 99th percentile that could be measured with 10% imprecision, as measured by coe⁄cient of variation (CV), should be used.
Attempts to de¢ne the 99th percentile for cardiac troponin include:
A study from Roche using their third generation troponin T assay (detection limit 0.010 mg/L); 19 of 1951 healthy persons (1%) had a concentration 40.010 mg/L;
A study byVenge et al. 8 of troponin I in 758 healthy persons using the Beckman Access II assay (detection limit 0.010 mg/L); the 99th percentile in healthy subjects was 0.020 mg/L.
Several troponin assay comparisons have been reported, 9 with various approaches to de¢ning reference or cut-o¡ limits:
(1) Report troponin concentration down to the assay detection limit: accurate discrimination between 'minor' myocardial injury and analytical noise requires assays that have high precision at this low troponin concentration. Further assay improvement will be required before this goal is achieved. Due to lack of standardization, a method that has a low limit of detection does not imply a sensitive assay. (2) Report down to a concentration corresponding to the 99th percentile concentration of a healthy reference population: problems remain with assay imprecision at these low concentrations. (3) Report down to a concentration corresponding to a CV of 20%, 'the functional sensitivity' of the assay: although myocardial damage is diagnosed more frequently, there is decreased con¢dence in that decision limit because it is close to the detection threshold. (4) Report down to a concentration corresponding to a CV of 10%: this was initially proposed byApple and Wu 10 and is now recommended by the National Academy of Clinical Biochemistry 11 and the International Federation of Clinical Chemistry (IFCC). 12 The European Society for Cardiology 7 and American College of Cardiology 7 consensus document supports the view that the acceptable imprecision for troponin methods, as measured by CV at the 99th percentile decision limit, should be p10%.
Opinion di¡ers about whether to use the 99th percentile reference limit or the lowest concentration associated with the 10% CV, with responses to the views of Apple et al. 13 stimulating further discussions around the justi¢cation of choosing 10% or 20% CV over the 99th percentile. Panteghini et al., 12 on behalf of the IFCC, evaluated the imprecision for cardiac troponin assays at low concentrations on various analysers and concluded that current assays were not able to achieve the 10% CV recommendation at the 99th percentile reference limit de¢ned by the manufacturers.
If the lowest concentration at which the 10% CV is achieved is used as the cut-o¡ level, however, this value will be relatively higher for a troponin assay with poorer precision at low concentrations. Therefore, the assay method used by a laboratory to measure troponin could determine whether or not a patient is classi-¢ed as having biochemical evidence of myocardial damage, resulting in wide variation in diagnosis. At an AllWales Clinical BiochemistryAudit Group meeting in 2004, it was agreed as a compromise that in order to reduce the inter-assay variability in interpretation, the cut-o¡ level chosen should be the concentration that can be reliably distinguished, with a con¢dence interval of 99%, from the 99th percentile reference limit.
Wales External Quality Assurance Scheme (WEQAS) study WEQAS undertook a study in 2004 to establish the intra-laboratory variation (both within and between batch) at a range of troponin concentrations for all laboratories in Wales, in order to obtain data to establish cut-o¡ concentrations. Five pools of human serum spiked with complexed troponin were prepared and stored at À701C until dispatch. Five sets of each pool were dispatched to all Welsh laboratories and stored at À201C until assay. A sample from each pool was assayed in duplicate on each of two runs on each day for ¢ve days, so each pool was assayed in duplicate on 10 occasions. Laboratories were asked to analyse samples as if they were patient's samples; calibration frequency and reagent lot numbers were laboratory-dependent. Analysis of the data from the study is summarized in Table 1 and discussed elsewhere in this issue. 14 
Recommended standards for biochemical markers of myocardial damage
The following standards are recommended, taking into account: 
Surveys of troponin measurements in

Chest pain protocols
An appropriate local protocol should be developed jointly by admitting physicians, cardiologists, emergency department sta¡, clinical laboratory sta¡ and hospital administrators, for the use of biochemical markers in the evaluation of patients with possible ACS. It should facilitate both the diagnosis and exclusion of ACS, and should be applicable to patients on admission or to those who are already in hospital. 11 
Choice of biochemical test: cardiac troponin (T or I) should be the first-line test
(a) Cardiac troponins are now the gold standard test for detecting myocardial damage. 11, 15, 16 They have high sensitivity and speci¢city for myocardial injury and remain abnormal for several days after the onset of symptoms.Whether troponin T or I is measured will depend on analyser availability; troponin T has advantages over troponin I because of lack of troponin I assay standardization and lack of good analytical correlation between commercial troponin I assays. (b) For detecting suspected re-infarction (up to10 days after the ¢rst episode), collection of serial blood samples over three consecutive days for CK (or CK-MB) should be considered, 11 because of the more rapid fall of CK (cardiac troponins have much longer half-lives). For CK-MB, immunometric assays, which measure CK-MB mass, are preferable to immunoinhibition assays of CK-MB activity. 17 
(c) Traditional 'cardiac enzymes' (AST, HBD and LDH)
no longer have any role in investigating myocardial damage, 11, 15 due to poor speci¢city and sensitivity and the need for serial samples. (d) Serum myoglobin is an early marker of myocardial damage that is increased in blood within 6 h of onset of symptoms. However, it has a low speci-¢city for cardiac damage and is only useful for ruling out AMI. It is of limited value in hospitals where triage decisions are not made within the ¢rst few hours after admission; 11 only cardiac troponin is then needed.
Relative roles of ECG and biochemical markers
In patients with characteristic ECG changes on admission (e.g. ST elevation), the diagnosis of AMI can be made and acute treatment initiated without immediate measurements of biochemical markers of cardiac damage. 11, 18 
Assay availability
This should be agreed with the clinical users of the service. Troponin assays should be available daily, including weekends and public holidays. If only a daytime service can be provided, results should be available as early as possible in the day to facilitate prompt clinical decision-making and optimal bed utilization. Troponin results should be available within 2 h of venepuncture when this service is required by senior clinicians.
Analytical interferences
Signi¢cantly haemolysed samples are unsuitable for troponin T. Fibrin and cell debris can give false-positive results with any sample type, particularly with some troponin I assays, as can heterophilic antibodies. Sta¡ should be trained to recognize potentially artefactual results and take steps to investigate unexpected results inconsistent with clinical ¢ndings (e.g. simple dilution studies, gamma globulin addition to neutralize heterophilic antibodies 21 
Interpretation
Laboratories should provide comments as appropriate on reports to remind non-specialist clinicians of the limitations of troponin assays. In particular:
(a) The troponin level may not be increased within the ¢rst 12 h after myocardial damage. (b) An increased troponin level indicates myocardial damage, but not its cause. The diagnosis of ACS/AMI must be supported with appropriate symptoms and/or ECG changes. In the absence of supportive clinical ¢ndings, other causes of myocardial damage should be considered. (c) The absolute troponin level may not reliably indicate the extent of myocardial damage. Other non-biochemical parameters, such as left ventricular function (ejection fraction), are better for this purpose.
Conclusions
These standards provide a rationale for a uniform approach to troponin assays in the investigation of patients with chest pain. The clinical implications of troponin concentrations above these cut-o¡ points are the subject of much current debate and require clari¢cation to enable standardization of the diagnosis and management of ACS and other conditions. Adherence to the recommended standards outlined here will place all laboratories in Wales on the same basis to aid that standardization of approach. The remaining biochemical challenge will be to determine equivalent values of troponin T and troponin I for identifying the same degree of myocardial damage in all laboratories. The outcome of the IFCC working group on the standardization of troponin I is eagerly awaited and will aid harmonization of troponin results.
